Press Detail

PRESS RELEASE

Biotest announces the opening of a plasma collection facility in Conway, Arkansas, US and the relocation of it's plasma collection Facility in San Antonio, Texas, US

- Total number of plasma collection centers in the US now eighteen.

Dreieich, 13 April, 2015. Biotest is pleased to announce the addition of its newest plasma collection in Conway, Arkansas, US. The over 16,000 square foot state-of-the-art facility officially opened its doors for business end of March 2015 and brings the total number of plasma collection centers in the US to eighteen.

"This facility represents another milestone in our continued efforts to strengthen our network of plasma collection centers and further reinforces our commitment to better serve the thousands of patients world-wide that rely on plasma based therapies" said Jordan Siegel, Biotest Pharmaceuticals Corporation (BPC), Chief Executive Officer. BPC is a wholly owned subsidiary of Biotest AG.

Moreover, Biotest is pleased to announce the relocation of its plasma collection in San Antonio, Texas. The 18,000 square foot state-of-the-art facility officially opened its doors for business on Sunday, March 29th 2015.

The plasma donated at Biotest Plasma Centers is used to manufacture critical care therapies that treat life threatening disorders in a variety of therapeutic areas, such as Bivigam^(R) (Immune Globulin Intravenous (Human), 10% Liquid) and Nabi-HB^(R) (Hepatitis B Immune Globulin (Human)).
The Company expects to add over fifty jobs to Conway's local economy. In addition, the center is actively recruiting local residents to donate plasma. Plasma donors not only contribute the source material for these plasma derived therapies that save the lives of thousands of patients but also are compensated for their donations.

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2.100 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart